Sorrento Therapeutics Inc.

12/07/2021 | Press release | Distributed by Public on 12/07/2021 12:53

Sorrento Begins Enrollment in Phase 2 Trial of Resiniferatoxin (RTX) for the Treatment of Pain Due to Knee Osteoarthritis (OA)